Richter Jumps as U.S. Approval Ends Years of Waiting for Drug

  • Cariprazine sales in U.S. may help offset declines in Europe
  • Ipopema analyst sees Richter sales jumping up to 30% by 2019

Hungarian drugmaker Gedeon Richter Nyrt., hit by eroding sales in some of its European markets, headed for the biggest gain in five months after U.S. authorities granted approval for an anti-psychotic drug developed jointly with Allergan Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.